BIOMAT Database Logo BIOMAT Database Logo

[Immunosuppressive therapy in polymyositis (author's transl)]. 1978

F Vergara, and P Ulloa, and A Reginato, and L Cartier

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009220 Myositis Inflammation of a muscle or muscle tissue. Inflammatory Myopathy,Myositis, Focal,Myositis, Infectious,Idiopathic Inflammatory Myopathies,Idiopathic Inflammatory Myopathy,Idiopathic Inflammatory Myositis,Infectious Myositis,Inflammatory Muscle Diseases,Inflammatory Myopathies, Idiopathic,Inflammatory Myopathy, Idiopathic,Muscle Diseases, Inflammatory,Myopathies, Idiopathic Inflammatory,Myopathy, Inflammatory,Myositis, Proliferative,Focal Myositides,Focal Myositis,Infectious Myositides,Inflammatory Muscle Disease,Inflammatory Myopathies,Muscle Disease, Inflammatory,Myopathies, Inflammatory,Myopathy, Idiopathic Inflammatory,Myositides,Myositides, Focal,Myositides, Infectious,Myositides, Proliferative,Proliferative Myositides,Proliferative Myositis
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F Vergara, and P Ulloa, and A Reginato, and L Cartier
Immunosuppressive therapy in polymyositis.
August 1971, Journal of neurology, neurosurgery, and psychiatry,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Immunosuppressive therapy in hematology (author's transl)].
May 1979, Therapeutische Umschau. Revue therapeutique,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Immunosuppressive therapy of polymyositis].
January 1975, Psychiatrie, Neurologie und medizinische Psychologie. Beihefte,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Immunosuppressive therapy of nephropathies (author's transl)].
May 1979, Therapeutische Umschau. Revue therapeutique,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Immunosuppressive therapy in renal disease (author's transl)].
December 1975, Wiener klinische Wochenschrift,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Immunosuppressive therapy following penetrating keratoplasty (author's transl)].
January 1980, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Pathogenesis of polymyositis (author's transl)].
May 1980, La Nouvelle presse medicale,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Penicillamine-induced polymyositis (author's transl)].
December 1974, Deutsche medizinische Wochenschrift (1946),
F Vergara, and P Ulloa, and A Reginato, and L Cartier
[Pathophysiology of infectious diseases in immunosuppressive therapy (author's transl)].
February 1976, Pathologie-biologie,
F Vergara, and P Ulloa, and A Reginato, and L Cartier
Plasmapheresis and immunosuppressive drug therapy in polymyositis.
September 1982, Muscle & nerve,
Copied contents to your clipboard!